BioVie reports improvement in 25% of Parkinson's patients receiving experimental drug bezisterim
Key Facts
BioVie presented data on its experimental Parkinson's disease drug bezisterim showing clinically meaningful improvement in 25% of participants who received it, compared with 4% on placebo. The presentation took place at the American Neurological Association meeting in San Diego, held on October 17–20, 2026, according to Investing.com coverage. These percentages relate to the composite benefit measure in the modified intent-to-treat analysis population, the measure used to assess the reported improvement. Clinically meaningful deterioration, meanwhile, occurred in 14% of the drug group, compared with 46% of the placebo group. The findings come from an exploratory Phase II study that the company said was intended to support preparations for the next stage of development.
The study enrolled 57 participants randomly assigned to receive bezisterim or placebo, according to trial design details reported by Investing.com. The drug group received a dose of 20 mg twice daily during the treatment period. Double-blind treatment lasted 12 weeks, within a study process that also included screening and safety follow-up. The primary pharmacodynamic assessment focused on changes in blood markers of inflammation, while other clinical measures assessed symptoms. The trial thus combined an assessment of changes in those blood markers with monitoring of clinical outcomes in the drug and placebo groups, within the same randomized design.
Bezisterim is an experimental oral drug that crosses the blood-brain barrier, according to coverage of the completion of patient visits in the study. That coverage describes it as targeting reduced inflammation and improved insulin sensitivity, the two pathways cited in the description of its pharmacological properties. The focus on inflammation comes within a program whose trial measured blood markers associated with it, alongside an assessment of clinical symptoms. Regarding the disease itself, the U.S. National Institute of Neurological Disorders and Stroke says there is "no cure for Parkinson's disease." The institute adds that medication or surgery can help patients move more easily and improve other symptoms, providing the treatment context in which the experimental drug is being developed.
On safety, the adverse event rate was 39.3% among participants in the bezisterim group, according to results reported by Investing.com. That compared with a rate of 51.7% in the placebo group during the study, putting the reported rate lower in the drug group. The company attributed the symptom improvement findings to the exploratory study analysis, with a statistical caveat concerning multiple comparisons. Coverage of the results described the statistical significance values as "nominal and unadjusted for multiple comparisons." This qualification remains part of the assessment of the reported improvement signals, alongside comparisons between the groups on both clinical outcomes and adverse events.
Topline study results had become available on August 6, 2026, according to dated coverage by Investing.com. The October update came with the presentation of trial data at the American Neurological Association meeting, following the program's initial announcement. In trading, BioVie shares rose 14.17% in the October 19, 2026 session, according to its historical price table. The stock closed that session at $1.3700, in the session preceding publication of the company's announcement on the presentation of its Parkinson's results. The rise preceded the conference announcement published the following day, while the trial's topline results had been public since August.
On the next development step, BioVie's chief executive said, in coverage of the completion of patient visits, that the study aimed to support finalizing the design of registration trials. He identified that step as Phase III trials, according to Investing.com's account of his explanation of the program's objective. He described the study's purpose as helping to "finalize the design of Phase III registration trials." That objective concerns preparing the design of upcoming trials, the development path the company aims to support through the current study. The San Diego presentation on October 17–20, 2026 formed part of the follow-up to this program, which moved from announcing topline results to presenting its data at the scientific meeting.